Pharmacist Mobile App Intervention in Pediatric Inpatient

NCT ID: NCT07254741

Last Updated: 2025-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-12

Study Completion Date

2024-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn whether a clinical pharmacist-led medication review, supported by medical mobile applications, can improve the safety and quality of care for hospitalized children. The study compares usual care with enhanced pharmacist involvement to understand whether this approach reduces medication-related problems and supports better clinical outcomes.

The main questions this study aims to answer are:

Does the pharmacist-led review help identify and prevent medication issues in pediatric inpatients?

Can this intervention improve the overall quality of care during hospitalization?

Does the use of mobile medical applications assist pharmacists in making safer medication decisions?

Participants will:

Receive either routine care or routine care plus daily medication review by a clinical pharmacist

Have their medications assessed regularly to identify potential problems

Be followed during their hospital stay to observe clinical outcomes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medication Safety in Pediatric Inpatients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacist-Led Medication Review

Group Type EXPERIMENTAL

Pharmacist-Led Medication Review

Intervention Type BEHAVIORAL

Daily medication review conducted by a clinical pharmacist using mobile medical applications to identify potential medication-related problems and support safer prescribing decisions for hospitalized pediatric patients.

Usual Care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist-Led Medication Review

Daily medication review conducted by a clinical pharmacist using mobile medical applications to identify potential medication-related problems and support safer prescribing decisions for hospitalized pediatric patients.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age between 2 and 15 years

Admitted to the pediatric general inpatient ward

Prescribed three or more medications during the hospital stay

Exclusion Criteria

Length of hospital stay less than 48 hours

Admission to the pediatric intensive care unit (PICU)

Estimated life expectancy less than 24 hours
Minimum Eligible Age

2 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beni-Suef University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Mohammed Abd Elhamid Mohammed Tony

Clinical Pharmacist and Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Coordination Unit

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

(FMBSUREC/03102023/Tony)

Identifier Type: -

Identifier Source: org_study_id